The Andrew Kung Lab
Research
The Kung Lab leverages patient-driven discovery to identify drivers and therapeutic vulnerabilities in pediatric and young adult cancers. The research infrastructure of the lab bridges the clinic, dry lab, and wet lab, with experimental data derived from model systems as well as in-human studies. We have developed a variety of experimental platforms to support the preclinical evaluation of promising agents including capabilities for in vitro drug screening, cell line development from patient tumor tissue, and in vivo testing in patient-derived xenograft (PDX) models. We have embraced computational biology approaches to predict genomically and non-genetically encoded tumor vulnerabilities, and utilize preclinical models to validate these therapeutic hypotheses.
Featured News
People
Andrew Kung, MD, PhD
Chair, Department of Pediatrics
- MD, Stanford University School of Medicine
Members
